Kompressionstherapie bei entzündlichen Dermatosen – Psoriasis vulgaris und Varikose

Zusammenfassung

Die Varikose, das Krampfaderleiden, stellt ein häufiges Krankheitsbild dar. Die Kompressionstherapie kommt hier standardmäßig zur Anwendung. Bei der Psoriasis vulgaris, einer chronisch-entzündlichen Hauterkrankung, können lokale Reize das Auftreten typischer Hautläsionen triggern. Ein örtlicher Zusammenhang psoriatischer Plaques und Varizen wird klinisch beobachtet. Im dargestellten Fall verhalf eine ergänzende Kompression zur Abheilung.

Abstract

In Germany, about 25% of the population show signs of chronic venous insufficiency (CVI).

Pathophysiologically, varicosis is based on a weakness of the vein wall, which can be attributed to a decrease in elastic fibres and muscle cells.

The main indications for medical compression therapy are chronic and thromboembolic venous diseases and oedema.

The effect of this therapy relies on different mechanisms, which lead to reduction in venous hypertension by reducing the venous vessel cross-section, promoting the venous return and activating the calf muscle pump.

It is clinically known that, in addition to external so-called exogenous stimuli, internal (endogenous) factors such as varicosis can also “trigger” dermatoses such as the psoriasis present in the case study.

In refractory psoriatic lesions of the lower extremities, a detailed history, clinical examination, and colour-coded duplex sonography should be performed to diagnose relevant concomitant venous diseases. Depending on the findings, additional compression therapy can be considered and, if necessary, further phlebological therapy can be initiated. Prospective studies should be planned to investigate the clinical impression and the pathophysiological relationship between therapy-resistant skin changes and varicosis.

Schlüsselwörter

Psoriasis - Varikose - Kompressionstherapie

Keywords

psoriasis - varicose veins - compression therapy

Publication History

Article published online:
14 March 2024

• Literatur

• 1 Rabe E, Berboth G, Pannier F. Epidemiology of chronic venous diseases. Wien Med Wochenschr 2016; 166: 260-263 DOI: 10.1007/s10354-016-0465-y. (PMID: 27277219)
• 2 Pannier F, Noppeney T, Alm J. et al. S2k guidelines: diagnosis and treatment of varicose veins. Hautarzt 2022; 73: 1-44 DOI: 10.1007/s00105-022-04977-8. (PMID: 35438355)
• 3 Rabe E, Pannier-Fischer F, Bromen K.. et al. Bonner Venenstudie der Deutschen Gesellschaft für Phlebologie. Phlebologie 2003; 32: 1-14
• 4 Lim CS, Davies AH. Pathogenesis of primary varicose veins. Br J Surg 2009; 96: 1231-1242 DOI: 10.1002/bjs.6798. (PMID: 19847861)
• 5 Segiet OA, Brzozowa-Zasada M, Piecuch A. et al. Biomolecular mechanisms in varicose veins development. Ann Vasc Surg 2015; 29: 377-384 DOI: 10.1016/j.avsg.2014.10.009. (PMID: 25449990)
• 6 Strölin A, Adamczyk A. et al. Erkrankungen der Venen. In: Plewig G, Ruzicka T, Kaufmann R. Braun-Falco’s Dermatologie, Venerologie und Allergologie. Berlin, Heidelberg: Springer; 2018: 1203-1225 DOI: 10.1007/978-3-662-49544-5_125
• 7 Rabe E, Foldi E, Gerlach H. et al. Medical compression therapy of the extremities with medical compression stockings (MCS), phlebological compression bandages (PCB), and medical adaptive compression systems (MAC) : S2k guideline of the German Phlebology Society (DGP) in cooperation with the following professional associations: DDG, DGA, DGG, GDL, DGL, BVP. German version. Hautarzt 2021; 72: 137-152 DOI: 10.1007/s00105-020-04734-9.
• 8 Weber B, Deinsberger J. Ulcus cruris venosum. hautnah 2022; 21: 43-50 DOI: 10.1007/s12326-022-00487-5.
• 9 Konschake W, Valesky E, Stege H. et al. Evidence of compression therapy. Hautarzt 2017; 68: 625-631 DOI: 10.1007/s00105-017-3999-z. (PMID: 28577055)
• 10 Partsch H. CHAPTER 10 – Mechanism and Effects of Compression Therapy. In: Bergan JJ. The Vein Book. Burlington: Academic Press; 2007: 103-109 DOI: 10.1016/B978-012369515-4/50013-2
• 11 Beidler SK, Douillet CD, Berndt DF. et al. Inflammatory cytokine levels in chronic venous insufficiency ulcer tissue before and after compression therapy. J Vasc Surg 2009; 49: 1013-1020 DOI: 10.1016/j.jvs.2008.11.049.
• 12 Schafer I, Rustenbach SJ, Radtke M. et al. Epidemiology of psoriasis in Germany – analysis of secondary health insurance data. Gesundheitswesen 2011; 73: 308-313 DOI: 10.1055/s-0030-1252022. (PMID: 20544588)
• 13 Ziob J. Kompressionstherapie bei Psoriasis vulgaris. vasomed 2021; 33: 51
• 14 Sampogna F, Gisondi P, Melchi CF. et al. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol 2004; 151: 594-599 DOI: 10.1111/j.1365-2133.2004.06093.x.
• 15 Nast A, Kopp IB, Augustin M. et al. Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 2007; 5: 1-119 DOI: 10.1111/j.1610-0387.2007.06172.x. (PMID: 17497162)
• 16 Ziob J, Heyer A-S, Berboth G. et al. P255 Varikose und das „endogene“ Köbner-Phänomen: Eine Fallserie. Poster der 50. DDG-Tagung. JDDG J Dtsch Dermatol Ges 2019; 17 (Suppl. 03) 80-211